Diabetes mellitus and wound healing

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 1133-1144

  Ganchi, Parham A ^a   Eriksson, Elof ^b,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971006608     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (247)

1. Morain W, Colen L. Wound healing in diabetes mellitus. Clin Plast Surg 1990;17:493-501.
2. Foster D. Diabetes mellitus. In: Fauci A, Braunwald E, Isselbacher K, et al., eds. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill, 1998:2060.
3. Levin M. Pathogenesis and management of diabetic foot lesions. In: Levin M, O'Neal L, Bowker J, eds. The diabetic foot. St. Louis: Mosby-Year Book, 1993:17.
4. Pryce T. Acase of perforating ulcers of both feet associated with diabetes and ataxic symptoms. Lancet 1887;2:11.
5. Bild D, Teutsch S. The control of hypertension in persons with diabetes: a public health approach. Public Health Rep 1987;102:522-529.
6. Stevens P. Growth and innovation strategies. Colleyville, TX, 2000.
7. Chittenden S, Shami S. Microangiopathy in diabetes mellitus: causes, prevention and treatment. Diabetes Res 1991;17:105-114.
8. Palumbo P, Melton L. Peripheral vascular disease and diabetes. In: National Diabetes Data Group, ed. Diabetes in America. Washington, DC: US Government Printing Office, 1985:1468.
9. Reiber G, Pecoraro R, Koepsell T. Risk factors for amputation in patients with diabetes mellitus. A case-control study. Ann Intern Med 1992;117:97-105.
10. Most R, Sinnock P. The epidemiology of lower extremity amputation in diabetic individuals. Diabetes Care 1983;87.
11. Reiber G. Diabetic foot care: financial implications and practical guidelines. Diabetes Care 1992;15[Suppl 1]:29-31.
12. Apelqvist J, Ragnarson-Tennvall G, Persson U, et al. Diabetic foot ulcers in a multi-disciplinary setting: an economic analysis of primary healing and healing with amputation. . Intern Med 1994;235:463-471.
13. Casey J, Flinn W, Yao J, et al. Correlation of immune and nutritional status with wound complications in patients undergoing vascular surgery. Surgery 1983;93:822-827.
14. Hjortrup C, Rasmussen B, Kehlet H. Morbidity in diabetic and non-diabetic patients after major vascular surgery. BMJ 1983;287:1107-1108.
15. Silhi N. Diabetes and wound healing. . Wound Care 1998;7:47-51.
16. Palmisano J. Surgery and diabetes. In: Kahn JR, Weir GC, eds. Joslin's diabetes mellitus, 13th ed. Philadelphia: Lea & Febiger, 1994:955-961.
17. Lawrie G, Morris G, Glaeser D. Influence of diabetes mellitus on the results of coronary bypass surgery: follow-up of 212 patients ten to 15 years after surgery. JAMA 1986;256:2967-2971.
18. Walsh D, Eckhauser F, Ramsburgh S, et al. Risk associated with diabetes mellitus in patients undergoing gallbladder surgery. Surgery 1982;91:254-257.
19. Hjortrup A, Sorensen C, Dyremose E. Influence of diabetes mellitus on operative risk. Br J Surg 1985;72:783-785.
20. Clement R, Rousou J, Engelman R, et al. Perioperative morbidity in diabetics requiring coronary artery bypass surgery. Ann Thorac Surg 1988;46:321-323.
21. Taitelman U, Reece E, Bessman A. Insulin in the management of the diabetic surgical patient, continuous intravenous infusion vs subcutaneous administration. JAMA 1977;237:658-660.
22. Gottrup F, Andreassen T. Healing of incisional wounds in stomach and duodenum: the influence of experimental diabetes. . Surg Res 1981;31: 61-68.
23. Goodson W, Hunt T. Wound healing and the diabetic patient. Surg Gynecol Obstet 1979;149:600.
24. Goodson W, Hunt T. Deficient collagen formation by obese mice in a standard wound model. Am J Surg 1979;138:692-694.
25. McMurry J. Wound healing with diabetes mellitus. Surg Clin North Am 1984;64:769-778.
26. Yue D, McLennan S, Marsh M, et al. Effects of experimental diabetes, uremia and malnutrition on wound healing. Diabetes 1987;36:295-299.
27. Yue D, Swanson B, McLennan S, et al. Abnormalities of granulation tissue and collagen formation in experimental diabetes, uremia and malnutrition. Diabet Med 1986;3:221-225.
28. Robertson H, Polk H. The mechanism of infection in patients with diabetes mellitus: a review of leukocyte malfunction. Surgery 1974;75:123-128.
29. Bagdade J, Stewart M, Walters E. Impaired granulocyte adherence: a reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 1978;27:677-681.
30. Molenaar D, Palumbo P, Wilson W, et al. Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives. Diabetes 1976;25 [Suppl 2]:880-883.
31. Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. . Engl J Med 1971;284:621-627.
32. Hostetter M. Handicaps to host defense: effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990;39:271-275.
33. Ward J, Tesfaye S. Pathogenesis of diabetic neuropathy. In: Pickup J, Williams G, eds. Textbook of diabetes. London: Blackwell Sciences, 1997:49.1.
34. Greene D, Feldman E, Stevens M. Neuropathy in the diabetic foot: new concepts in etiology and treatment. In: Levin M, O'Neal L, Bowker L. eds. The diabetic foot. St. Louis: Mosby-Year Book, 1993:135.
35. Melton L, Dyck P. Epidemiology. In: Dyck P, Thomas P, Asbury A, eds. Diabetic neuropathy, Philadelphia: WB Saunders, 1987.
36. Watkins P, Edmonds M. Clinical features of diabetic neuropathy. In: Pickup J, Williams G, eds. Textbook of diabetes. London: Blackwell Sciences, 1997; 50.1.
37. Thomas P, Brown P. Diabetic polyneuropathy. In: Dyck P, Thomas P, Asbury A, eds. Diabetic neuropathy. Philadelphia: WB Saunders, 1987.
38. Dyck P, Sherman W, Hallcher L. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-596.
39. Brown M, Martin J, Asbury A. Painful diabetic neuropathy: a morphometric study. Arch Neurol 1976;33:164-167.
40. Dyck P, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci U S A 1985;52:2513-2517.
41. Hill M, Colen L, Vinik A. Microvascular and compression mechanisms in the etiology of diabetic neuropathy. In: LeRoith D, Taylor S, Olefsky J, eds. Diabetes mellitus. Philadelphia: Lippincott-Raven Publishers, 1996:759.
42. Llewelyn J, Gilbey S, Thomas B, et al. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy: a clinicopathological study. Brain 1991;44:867-892.
43. Simmons DA. Pathogenesis of diabetic neuropathy. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus, 13th ed. Philadelphia: Lea & Febiger, 1994: 665-690.
44. Greene D, Sima A, Albers J. Diabetic neuropathy. In: Rifkin H, Porte D, eds. Diabetes mellitus, theory and practice. St. Louis: Mosby-Year Book, 1990.
45. Boulton A, Knight G, Drury J, et al. The prevalence of symptomatic diabetic neuropathy in an insulin treated population. Diabetes Care 1985;8:125-128.
46. Lehtinen J, Uusitupa M, Siitonen O, et al. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989;38:1307-1313.
47. Maser R, Steenkiste A, Dorman J, et al. Epidemiological correlates of diabetic neuropathy. Diabetes 1989;8:1456-1461.
48. Neil H, Thompson A, John S, et al. Prevalence of diabetic neuropathy in a community. Diabet Med 1989;6:20.
49. Young M, Boulton A, MacLeod A, et al. Amulticentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom Hospital clinic population. Diabetologia 1993;36:150-153.
50. Newrick P, Boulton A, Ward J. The distribution of diabetic neuropathy in a British clinic population. Diabetes Res Clin Pract 1986;2:263.
51. DCCT Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetologia 1988;37:476-481.
52. Porte D, Graf R, Halter J, et al. Diabetic neuropathy and plasma glucose control. Am J Med 1981;70:195-200.
53. Thomas P. Diabetic neuropathy: models, mechanisms and mayhem. Can J Neurol Sci 1992;19:1-7.
54. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1978; 1:168.
55. Harati Y. Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin 1992;10:783-807.
56. Canal N, Comi G, Saibene V. The relationship between peripheral and autonomic neuropathy in insulin dependent diabetes: a clinical and instrumental evaluation. In: Canal N, Pozza G, eds. Peripheral neuropathies. Amsterdam: Elsevier, 1978:247.
57. Fernandez-Castaner M, Mendola G, Levy I. The prevalence and clinical aspects of the cardiovascular autonomic neuropathy in diabetic patients [in Spanish]. Med Clin (Barc) 1984;84:215.
58. Ewing D, Clarke B. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986;9:648-665.
59. O'Brien I, O'Hare J, Lewin I, et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. . J Med 1986;61:957-967.
60. Krolewski A, Warram J, Cupples A, et al. Hypertension, orthostatic hypotension and the microvascular complications of diabetes. . Chronic Dis 1985;38:319-326.
61. Caputo G, Cavanagh P, Ulbrecht J, et al. Assessment and management of foot disease in patients with diabetes. . Engl J Med 1994;331:854-521.
62. Pecoraro P, Reiber G, Burgess E. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990;13:513-521.
63. Boulton A. The diabetic foot: neuropathic in aetiology? Diabet Med 1990; 7:852-858.
64. Boulton A. Peripheral neuropathy and the diabetic foot. The Foot 1992;2:67.
65. Young M, Breddy J, Veves A, et al. The prediction of neuropathic foot ulceration using vibration perception thresholds. Diabetes Care 1994;17:557-560.
66. Sosenko J, Kato M, Sozo R, et al. Comparison of quantitative sensorythreshold measures for their association with foot ulceration in diabetic patients. Diabetes Care 1990;13:1057-1061.
67. Birke J, Sims D. Plantar sensory threshold in the ulcerative foot. Lepr Rev 1986;57:261.
68. Klenerman L, McCabe C, Cogley D, et al. Screening for patients at risk of diabetic foot ulceration in a general diabetic outpatient clinic. Diabet Med 1996;13:561-563.
69. Edmonds M, Roberts V, Watkins P. Blood flow in the diabetic neuropathic foot. Diabetologia 1982;22:9-15.
70. Watkins P, Edmonds M. Sympathetic nerve failure in diabetes. Diabetologia 1983;25:73-77.
71. Flynn M, Edmonds M, Tooke J, et al. Direct measurement of capillary blood flow in the diabetic neuropathic foot. Diabetologia 1988;31:652-656.
72. Archer A, Watkins P, Roberts V. Blood flow patterns in painful diabetic neuropathy. Diabetologia 1984;27:563-567.
73. Boulton A, Scarpello J, Ward J. Venous oxygenation in the diabetic neuropathic foot: evidence of arteriovenous shunting? Diabetologia 1982;22:6-8.
74. Edmonds M, Archer A, Watkins P. Ephedrine: a new treatment for diabetic neuropathic oedema. Lancet 1;1983;548-551.
75. Boulton A. Foot problems in patients with diabetes mellitus. In: Pickup J, Williams G, eds. Textbook of diabetes. London: Blackwell Sciences, 1997:58.1.
76. Edmonds M, Clarke M, Newton S, et al. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. . J Med 1985;57:843-855.
77. Veves A, Murray H, Young M, et al. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetologia 1992;35: 660-663.
78. Macfarlane R, Jeffcoate W. Factors contributing to the presentation of diabetic foot ulcers. Diabet Med 1997;14:867-870.
79. Young M, Cavanagh P, Thomas G, et al. Effect of callus removal on dynamic foot pressures in diabetic patients. Diabet Med 1992;9:55-57.
80. Murray H, Young M, Boulton A. Relationship between callus formation, pressures and neuropathy in diabetic foot ulceration. Diabet Med 1994;11 [Suppl 2]:5.
81. Service F, Rizza R, Daube J. Near normoglycaemia: improved nerve conduction and vibration sensation in diabetic neuropathy. Diabetologia 1985;28:722-727.
82. Kennedy W, Navarro X, Goetz F, et al. Effects of pancreatic transplantation on diabetic neuropathy. . Engl J Med 1990;322:1031-1037.
83. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
84. Greene D, Sima A, Stevens M, et al. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902-1925.
85. Greene D, Lattimer S, Sima A. Sorbitol, phosphoinositides and sodiumpotassium-ATPase in the pathogenesis of diabetic complications. . Engl J Med 1987;316:599-606.
86. Dvornik D. Hyperglycemia in the pathogenesis of diabetic complications. In: Porte D, ed. Aldose reductase inhibition: an approach to the prevention of diabetic complications. New York: McGraw-Hill, 1987:69.
87. Tuck R, Schmelzer J, Low P. Endoneurial blood flow and oxygen tension in the sciatic nerve of rats with experimental diabetic neuropathy. Brain 1984;107:935.
88. Cameron N, Cotter M, Low P. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991;261:E1.
89. Cameron N, Cotter M, Ferguson K. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na/K-ATPase activity, and vascular supply in STZ-D rats. Diabetes 1991;40:1652-1658.
90. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835.
91. Richard S, Tamas C, Sell D, et al. Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationship to pentosidine cross-links. Diabetes 1991;40:1049-1056.
92. Moncada S, Palmer R, Higg E. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
93. Gryglewski R, Palmer R, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320: 454-456.
94. Bertelsmann F, Faes T, de Weerdt O. Treatment of diabetic autonomic neuropathy with the aldose reductase inhibitor Statil. Diabetologia 1991;34[Suppl 2]:A37.
95. Boulton A, Levin S, Comstock JA. multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431-437.
96. Christensen J, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study. Acta Neurol Scand 1985;71:164-167.
97. Young R, Ewing D, Clark B. Acontrolled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983;32:938-942.
98. Greene D, Stevens M. The sorbitol-osmotic and sorbitol-redox hypotheses. In: LeRoith S, Taylor S, Olefsky J, eds. Diabetes mellitus. Philadelphia: Lippincott-Raven Publishers, 1996:801.
99. Moriyama T, Garcia-Perez A, Burg M. High extracellular NaCl stimulates synthesis of aldose reductase, an osmoregulatory protein, in renal medullary cells. Kidney Int 1989;35:499.
100. Kwon MH, Yamauchi A, Uchida S. Renal Na-myo-inositol cotransporter mRNA expression in Xenopus oocytes: regulation by hypertonicity. Am J Physiol 1991;260:F258-F263.
101. Burg M, Kador P. Sorbitol, osmoregulation, and the complications of diabetes. . Clin Invest 1988;81:635-640.
102. Tomlinson D. Polyols and myoinositol in diabetic neuropathy-of mice and men. Mayo Clin Proc 1989;64:1030-1033.
103. Stevens M, Lattimer S, Kamijo M. Osmotically induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993;36:608-614.
104. Griffey R, Eaton R, Sibbitt R. Diabetic neuropathy: structural analysis of nerve hydration by magnetic resonance spectroscopy. JAMA 1988;260:2872-2878.
105. Huxtable R. From heart to hypothesis: a mechanism for the calcium modulatory effects on actions of taurine. In: Huxtable R, Franconi F, Giotti A, eds. The biology of taurine: methods and mechanisms. New York: Plenum Press, 1987:371.
106. Malone J, Lowitt S, Cook W. Nonosmotic diabetic cataracts. Pediatr Res 1990;27:293-296.
107. Lombardi J. Effects of taurine on calcium ion uptake and protein phosphorylation in rat retinal membrane preparations. . Neurochem 1985;45:268.
108. Nakamura J, Del Monte M, Shewach D. Inhibition of phosphatidylinositol synthase by glucose in human retinal pigment epithelial cells. Am J Physiol 1992;262:E417-E426.
109. Cheung W. Calmodulin plays a pivotal role in cellular regulation. Science 1980;207:19-27.
110. Nestler E, Greengard P. Protein phosphorylation in the brain. Nature 1983; 305:583.
111. Greene D, De Jesus P, Winegrad A. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. . Clin Invest 1975;55:1326-1336.
112. Greene D, Lattimer S, Ulbrecht J, et al. Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 1985;8:290-299.
113. Greene D, Lattimer S. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity. Diabetes 1984;33:712-714.
114. Tomlinson D, Sidenius P, Larsen JR. Slow component-a of axonal transport, nerve myo-inositol and aldose reductase inhibition in streptozotocin-diabetic rats. Diabetes 1986;35:398-402.
115. Tomlinson D, Mayer J. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin diabetic rats with myo-inositol. Exp Neurol 1985;89:420-427.
116. Finegold D, Lattimer S, Nolle S. Polyol pathway activity and myo-inositol metabolism: a suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 1983;32:988.
117. Lambourne J, Tomlinson D, Brown A, et al. Opposite effects of diabetes and galactosaemia on adenosine triphosphatase activity in rat nervous tissue. Diabetologia 1987;30:360-362.
118. Llewelyn J, Patel N, Thomas P. Sodium, potassium adenosine triphosphatase activity in peripheral nerve tissue of galactosaemic rats. Effects of aldose reductase inhibition. Diabetologia 1987;30:971-972.
119. Hale P, Nattrass M, Silverman S. Peripheral nerve concentrations of glucose, fructose, sorbitol and myoinositol in diabetic and non-diabetic patients. Diabetologia 1987;30:464-467.
120. Dyck P, Zimmerman B, Vilen T, et al. Nerve glucose, fructose, sorbitol, myoinositol, and fibre degeneration and regeneration in diabetic neuropathy. . Engl J Med 1988;319:542-548.
121. Cameron N, Cotter M. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994;10:189-224.
122. Moncada S, Palmer R, Higgs E. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication. Biochem Pharmacol 1989;38:1709-1715.
123. Durante W, Sen A, Sunahara F. Impairment of endothelium-dependent relaxation in aorta from spontaneously diabetic rats. Br J Pharmacol 1988;94:463-468.
124. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocininduced diabetic rats. Br J Pharmacol 1989;97:614-618.
125. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arterial tone in man. Lancet 1989;2:997-1000.
126. Carroll P, Thornton B, Greene D. Glutathione redox state is not the link between polyol pathway activity and diminished (Na, K)-ATPase activity in experimental diabetic neuropathy. Diabetes 1986;35:1282-1285.
127. Garthwaite J, Charles S, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988;336:385-388.
128. Stevens M, Dananberg J, Feldman E, et al. The linked roles of nitric oxide, aldose reductase and (Na, K)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. . Clin Invest 1994;94:853-859.
129. Rapoport R, Murad F. Agonist-induced endothelium-dependent relaxation in the rat thoracic aorta may be mediated through cGMP. Circ Res 1983;52: 352-357.
130. Hammes H-P, Brownlee M. Advanced glycation end products and the pathogenesis of diabetic complications. In: LeRoith D, Taylor, Olefsky J, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott-Raven Publishers, 1996:810.
131. Cullum N, Mahon J, Stringer K, et al. Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus. Diabetologia 1991;34:387-389.
132. Kihara M, Schmelzer M, Poduslo J, et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals. Proc Natl Acad Sci U S A 1991;88:6107-6111.
133. Cameron N, Cotter M, Dines K, et al. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocindiabetic rats. Diabetologia 1992;35:946-950.
134. Laing P. The development and complications of diabetic foot ulcers. Am J Surg 1998;176[Suppl 2A]:11S.
135. Abbott R, Brand F, Kannel W. Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study. Am J Med 1990;88:376-381.
136. Wellman K, Volk B. Historical review. In: Volk B, Wellman K, ed. The diabetic pancreas. New York: Plenum Press, 1977:1.
137. McNeely M, Boyko E, Ahroni J, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995;18:216-219.
138. Thompson F, Veves A, Ashe H. A team approach to diabetic foot care: the Manchester experience. The Foot 1991;1:75.
139. Edmonds M. Experience in a multi-disciplinary diabetic foot clinic. In: Connor H, Boulton A, Ward J, eds. The foot in diabetes. Chichester: John Wiley and Sons, 1987:121.
140. Holewski J, Moss K, Sless R. Prevalence of foot pathology and lower extremity complications in a diabetic outpatient clinic. . Rehabil Res Dev 1989; 26:35.
141. Edmonds M, Blundell M, Morris H. The diabetic foot: impact of a foot clinic. . J Med 1986;232:763.
142. Caldwell M, Shearer J, Morris A, et al. Evidence for aerobic glycolysis in lambda-carrageenan wounded skeletal muscle. . Surg Res 1984;37:63-68.
143. MacKaay A, Beks P, Dur A, et al. The distribution of peripheral vascular disease in a Dutch caucasian population: comparison of type II diabetic and non-diabetic subjects. Eur J Vasc Endovasc Surg 1995;9:170-175.
144. Janka H, Standl E, Mehnert H. Peripheral vascular disease in diabetes mellitus and its relation to cardiovascular risk factors: screening with Doppler ultrasonic technique. Diabetes Care 1980;3:207-213.
145. Levin M, Sicard G. Evaluating and treating diabetic peripheral vascular disease: part I. Clin Diabetes 1987;5:62.
146. Logerfo F, Gibbons G. Vascular disease of the lower extremities in diabetes mellitus: etiology and management. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus, 13th ed. Philadelphia: Lea & Febiger, 1994: 970-975.
147. Conrad M. Large and small artery occlusion in diabetics and nondiabetics with severe vascular disease. Circulation 1967;36:83-91.
148. Strandness D, Priest R, Gibbons G. Combined clinical and pathologic study of diabetic and nondiabetic peripheral arterial disease. Diabetes 1964;13:366-372.
149. Cantelmo N, Snow J, Menzoian J, et al. Successful vein bypass in patients with an ischemic limb and a palpable popliteal pulse. Arch Surg 1986;121: 217-220.
150. Stonebridge P, Tsoukas A, Pomposelli F, et al. Popliteal-to-distal bypass grafts for limb salvage in diabetics. Eur J Vasc Surg 1991;5:265-269.
151. Auer A, Hurley J, Binnington H, et al. Distal tibial vein grafts for limb salvage. Arch Surg 1983;118:597-602.
152. Reiber G, Lipsky B, Gibbons G. The burden of diabetic foot ulcers. Am J Surg 1998;176[Suppl 2A]:5S.
153. Goldenberg S, Alex M, Joshi R. Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. Diabetes 1959;8:261-273.
154. Barner H, Kaiser G, Willman V. Blood flow in the diabetic leg. Circulation 1971;43:391-394.
155. Wyss C, Matsen F, Simmons C, et al. Transcutaneous oxygen tension measurements on limbs of diabetic and nondiabetic patients with peripheral vascular disease. Surgery 1994;95:339-346.
156. Krahenbuhl B, Mossaz A. On vascular non-disease of the foot in diabetes. . Engl J Med 1985;312:1190-1191.
157. LoGerfo F, Coffman J. Current concepts: vascular and microvascular disease of the foot in diabetes: implications for foot care. . Engl J Med 1984;311: 1615-1619.
158. McMillan D. The microcirculation in diabetes. Microcirc Endothel Lymph 1984;1:3.
159. Isogai Y, Iida A, Michizuki K, et al. Hemorheological studies on the pathogenesis of diabetic microangiopathy. Thromb Res 1976;8[Suppl 2]:17-24.
160. McMillan D, Utterback N, LaPuma J. Reduced erythrocyte deformity in diabetes. Diabetes 1982;31[Suppl 3]:64.
161. Maeda N, Kon K, Imiazumi I. Alteration of rheological properties of human erythrocytes by crosslinking of membrane proteins. Biochim Biophys Acta 1983;735:104-112.
162. Bridges J, Dalby A, Millar J. An effect of D-glucose on platelet stickiness. Lancet 1965;1:75.
163. Thomas P, Eliason S. Diabetic neuropathy. In: Dyck P, Thomas P, Lambert E, eds. Peripheral neuropathy. Philadelphia: WB Saunders, 1984:1173.
164. Simpson L. Intrinsic stiffening of red blood cells as the fundamental cause of diabetic nephropathy and microangiopathy: a new hypothesis. Nephron 1985;39:344-351.
165. Juhan L, Bunoacare M, Jouve R. Abnormalities of erythrocyte deformability and platelet aggregation in insulin-dependent diabetics corrected by insulin in vivo and in vitro. Lancet 1982;1:535.
166. Schmid-Schonbein H, Wells R, Goldstone J. Influence of deformability of human red cells upon blood viscosity. Circ Res 1969;25:131-143.
167. Ditzel J. Changes in red cell oxygen release capacity in diabetes mellitus. Fed Proc 1979;38:2484-2488.
168. McDonald M, Bleichman M, Bunn H, et al. Functional properties of the glycosylated minor components of human hemoglobin. . Biol Chem 1979;254: 702-707.
169. Goodson W, Hunt T. Wound collagen accumulation in obese hyperglycaemic mice. Diabetes 1986;35:491-495.
170. Flynn M, Tooke J. Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabet Med 1992;8:320-329.
171. Klamer T, Towne J, Bandyk D. The influence of sepsis and ischemia on the natural history of the diabetic foot. Am Surg 1987;53:490-494.
172. Cruse P, Foord R. A five-year prospective study of 23,649 surgical wounds. Arch Surg 1973;107:206.
173. Boyko E, Lipsky B. Infection and diabetes mellitus. In: National Diabetes Data Group. Diabetes in America, 2nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 1995:485. NIDDKD publication 95-1468.
174. Spelman D, Russo P, Harrington G, et al. Risk factors for surgical wound infection and bacteremia following coronary artery bypass surgery. Aust N Z J Surg 2000;70:47-51.
175. Carpino P, Khabbaz K, Bojar R, et al. Clinical benefits of endoscopic vein harvesting in patients with risk factors for saphenectomy wound infections undergoing coronary artery bypass grafting. . Thorac Cardiovasc Surg 2000; 119: 69-75.
176. Allen K, Griffith G, Heimansohn D, et al. Endoscopic versus traditional saphenous vein harvesting: a prospective randomized trial. Ann Thorac Surg 1998;66:26-31.
177. Borger M, Rao V, Weisel R, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998;65:1050-1056.
178. Zerr K, Furnary A, Grunkemeier G, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997;63:356-361.
179. Shpitz B, Sigal A, Kaufman Z, et al. Acute cholecystitis in diabetic patients. Am Surg 1995;61:964-967.
180. Babineau T, Bothe A. General surgery considerations in the diabetic patient. Infect Dis Clin North Am 1995;9:183-193.
181. Grossi E, Esposito R, Harris L, et al. Sternal wound infections and use of internal mammary artery grafts. Cardiovasc Surg 1991;102:342-346.
182. Hickman M, Schwesinger W, Page C. Acute cholecystitis in the diabetic: a case-control study of outcome. Arch Surg 1988;123:409-411.
183. Josephs L, Cordts P, DiEdwardo C, et al. Do infected inguinal lymph nodes increase the incidence of postoperative groin wound infection? . Vasc Surg 1993;17:1077-1080.
184. Wymenga A, van Horn J, Theeuwes A, et al. Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand 1992;63:665-671.
185. Robison J, Ross J, Brothers T, et al. Distal wound complications following pedal bypass: analysis of risk factors. Ann Vasc Surg 1995;9:53.
186. Lipsky B, Pecoraro R, Wheat J. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990;4:409-432.
187. Frykberg R, Veves A. Diabetic foot infections. Diabetes Metab Rev 1996;12: 255-270.
188. Lipsky B, Pecoraro R, Ahroni J. Foot ulceration and infections in elderly diabetics. Clin Geriatr Med 1990;6:747-769.
189. Sapico F, Witte J, Canawati H, et al. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984;6[Suppl 1]:S171-S176.
190. Pozzilli P, Leslie R. Infections and diabetes: mechanisms and prospects for prevention. Diabet Med 1994;11:935-941.
191. Goodson W, Hunt T. Wound healing in experimental diabetes mellitus, importance of early insulin therapy. Surg Forum 1978;29:95-98.
192. Goodson W, Hunt T. Studies of wound healing in experimental diabetes mellitus. . Surg Res 1987;22:221.
193. Nolan C, Beaty H, Bagdade J. Further characterization of the impaired bacteriocidal function of granulocytes in patients with poorly controlled diabetes. Diabetes 1978;27:889-894.
194. Bybee J, Rogers D. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. . Lab Clin Med 1964;64:1.
195. Bagdade J, Walters E. Impaired granulocyte adherence in mildly diabetic patients: effects of tolazamide treatment. Diabetes 1980;29:309-311.
196. Bagdade J, Root R, Bugler R. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974;23:9-15.
197. Tan J, Anderson J, Watanakunakorn D, et al. Neutrophil dysfunction in diabetes mellitus. . Lab Clin Med 1975;85:26-33.
198. Ainsworth S, Allison F. Studies on the pathogenesis of acute inflammation: the inflammatory response induced by thermal injury to ear chambers of rabbits. . Clin Invest 1970;49:433-441.
199. Brayton R, Stokes P, Schwarz M. Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis and intracellular bacterial killing. . Engl J Med 1970;282:123-128.
200. Stadelmann W, Digenis A, Tobin G. Impediments to wound healing. Am J Surg 1998;176[Suppl 2A]:39S.
201. Bagdade J, Nielson K, Bulger R. Reversible abnormalities in phagocytic function in poorly controlled diabetes. Am J Med Sci 1972;263:451-456.
202. Caricco T, Mehrhof A, Cohen I. Biology of wound healing. Surg Clin North Am 1984;64:721-733.
203. Rosenberg C. Wound healing in the patient with diabetes mellitus. Nursing Clin North Am 1990;25:247-261.
204. Pecoraro R, Chen M. Ascorbic acid in diabetes mellitus. Ann N Y Acad Sci 1987;498:248-256.
205. Miller M, Baker L. Leukocyte functions in juvenile diabetes mellitus: humoral and cellular aspects. . Pediatr 1972;81:979-982.
206. Repine J, Clawson C, Goetz F. Bactericidal function of neutrophils from patients with acute bacterial infection and from diabetics. . Infect Dis 1980; 142:869-875.
207. Gin H, Brottier E, Aubertin J. Influence of glycaemic normalisation on phagocytic and bactericidal functions of granulocytes in insulin dependent diabetes patients. . Clin Pathol 1984;37:1029-1031.
208. Weringer E, Kelso J, Tamai I. The effect of insulin 2-deoxyglucose-induced hyperglycemia and starvation on wound healing in normal mice. Diabetes 1981;30:407-410.
209. Arquilla E, Weringer E, Nakajo M. Wound healing: a model for the study of diabetic angiopathy. Diabetes 1976;25[Suppl 2]:811-819.
210. Snip RC, Thoft R, Tolentino F. Similar epithelial healing rates of the corneas of diabetic and nondiabetic patients. Am J Ophthalmol 1980;90:463-468.
211. Fowler S. Wound healing in the corneal epithelium in diabetic and normal rats. Exp Eye Res 1980;31:167-179.
212. Seifter E, Rettura G, Padawer J, et al. Impaired wound healing in streptozotocin diabetes, prevention by supplemental vitamin A. Ann Surg 1981;194: 42-50.
213. Engel E, Erlick N, Davis R. Diabetes mellitus: impaired wound healing from zinc deficiency. . Am Podiatry Assoc 1981;71:536-544.
214. Kohn R, Hensse S. Abnormal collagen in cultures of fibroblasts from diabetic patients. Biochem Biophys Res Comm 1978;76:765.
215. Grotendorst G, Martin G, Pencev D, et al. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. . Clin Invest 1985;76:2323-2329.
216. Alberti K, Press C. The biochemistry of the complications of diabetes mellitus. In: Keen H, Jarrett J, ed. Complications of diabetes. London: Edward Arnold, 1992.
217. Reiber G, Vileikyte L, Boyko E, et al. Causal pathways for incident lowerextremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157-162.
218. Griffiths G, Wieman T. Meticulous attention to foot care improves the prognosis in diabetic ulceration. Surg Gynecol Obstet 1992;174:49.
219. Dyck P. New understanding and treatment of diabetic neuropathy. . Engl J Med 1992;326:1287-1288.
220. Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. Arch Surg 1985;120:267-270.
221. Oberg M, Lindsey D. Do not put hydrogen peroxide or povidone iodine in wounds! Am J Dis Child 1987;141:27-28.
222. Svensjo T, Pomahac B, Yao F, et al. Accelerated healing of full-thickness skin wounds in a wet environment. Plast Reconstr Surg 2000;106:602-612.
223. Field C, Kerstein M. Overview of wound healing in a moist environment. Am J Surg 1993;167[Suppl 1A]:2S-6S.
224. Smiell J. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Study Group. Am J Surg 1998;176[Suppl 2A]:68S-73S.
225. Smiell J, Wieman T, Steed D, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999;7:335-346.
226. Wieman T. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Study Group. Am J Surg 11998;76[Suppl 2A]:74S-79S.
227. Embil J, Papp K, Sibbald G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen 2000;8: 162-168.
228. Temple M, Nahata M. Pharmacotherapy of lower limb diabetic ulcers. . Am Geriatr Soc 2000;48:822-828.
229. Ladin D. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee. Plast Reconstr Surg 2000; 105:1230-1231.
230. Pecoraro R, Ahroni J, Boyko E, et al. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 1991;40:1305-1313.
231. Sage R, Doyle D. Surgical treatment of diabetic foot ulcers: a review of fortyeight cases. . Foot Surg 1984;23:102-111.
232. Dickhaut S, Delee J, Page C. Nutritional status: importance in predicting wound-healing after amputation. . Bone Joint Surg 1984;66:71-75.
233. Levin M, Spratt I. To soak or not to soak. Clin Diabetes 1986;4:44.
234. Laing P. Diabetic foot ulcers. Am J Surg 1994;167[Suppl 1A]:31S-36S.
235. Mueller M, Diamond J, Sinacore D, et al. Total contact casting in the treatment of diabetic plantar ulcers: controlled clinical trial. Diabetes Care 1989;12:384-388.
236. Burden A, Jones G, Jones R, et al. Use of the "Scotchcast boot" in treating diabetic foot ulcers. BMJ 1983;286:1555-1557.
237. Coleman W, Brand P. The diabetic foot. In: Porte D, Sherwin R, eds. Diabetes mellitus. Stamford, CT: Appleton & Lange, 1997:1159.
238. Orr H. The principles involved in the treatment of osteomyelitis and compound fractures. Lancet 1934;54:622.
239. Trueta J. Treatment of war wounds and fractures. BMJ 1942;1:616.
240. Brand P. Insensitive feet: a practical handbook on foot problems in leprosy. London: The Leprosy Mission, 1977.
241. Sinacore D, Mueller M, Diamond J, et al. Diabetic plantar ulcers treated with total-contact casting: a clinical report. Phys Ther 1987;67:1543-1549.
242. Walker S, Helm P, Pullium G. Total-contact casting and chronic diabetic neuropathic foot ulcerations: healing rates by wound location. Arch Phys Med Rehabil 1987;68:217-221.
243. Laing P, Cogley D, Klenerman L. Neuropathic foot ulceration treated by total contact casts. . Bone Joint Surg [Br] 1991;4:133.
244. Husband M, Carr J. A simplified method of total contact casting for diabetic foot ulcers. Contemp Orthop 1993;26:143.
245. Helm P, Walker S, Pullium G. Total contact casting in diabetic patients with neuropathic foot ulcerations. Arch Phys Med Rehabil 1984;65:691-693.
246. Myerson M, Papa J, Eaton K, et al. The total-contact cast for management of neuropathic ulceration of the foot. . Bone Joint Surg 1992;74:261-263.
247. Edmonds M, Blundell M, Morris M, et al. Improved survival of the diabetic foot: the role of a specialized foot clinic. . J Med 1986;60:763-771.